Scroll To Top
Health

Incyte stops
development of anti-HIV drug

Incyte stops
development of anti-HIV drug

Drug development halted after reports of pancreatic inflammation.

Sorry to interrupt...
But we wanted to take a moment to thank you for reading. Your support makes original LGBTQ+ reporting possible. Help us hold Trump accountable.

Pharmaceutical company Incyte on Monday announced that it has halted developed on its experimental HIV nucleoside reverse transcriptase inhibitor DFC, formerly known as Reverset, because the drug boosted risks for pancreatic inflammation. Researchers noted an increased level of grade 4 hyperlipasemia, a marker of pancreatic inflammation, in the Phase II-b study. Based on the study findings, Incyte announced it has halted enrollment in the clinical trial and will begin working with the Food and Drug Administration to find alternative treatments for the study participants who have drug-resistant virus and few other treatment options. (The Advocate)

The Advocates with Sonia BaghdadyOut / Advocate Magazine - Alan Cumming and Jake Shears

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff